# Precision Monitoring: Standardizing Patient-Reported Signals to Improve Clinical Decision-Making Using Real-World Data

Nathan Uk, PharmD · Misha Kaur, PhDc · Max Hardy-Werbin, PhD, MD · Marc Sorigué, MD, PhD · Maryam Lustberg, MD · Florian Scotte, MD

## Introduction

- Advances in cancer treatment have increased the complexity of toxicity management while shifting more care beyond the clinic into outpatient and home settings.
- Remote symptom monitoring has demonstrated improvements in clinical outcomes, patient experience and healthcare utilization. However, broad implementation remains limited by variability in symptom assessment, inconsistent clinical interpretation and the lack of standardized monitoring frameworks.
- Standardizing patient-reported symptom signals using validated frameworks offer opportunities to improve the consistency of toxicity assessment, support earlier clinical intervention, enable longitudinal monitoring and generate high-quality real-world evidence.
- The Cureety precision monitoring approach applies treatment-specific, CTCAE-aligned patient-reported questionnaires and standardized triage classification to support proactive toxicity management across routine oncology practice.

## Objectives

- Demonstrate feasibility and benefits of remote monitoring in oncology through real-world evidence and large system implementation.
- Describe patient-reported toxicity patterns across diverse cancer treatment types.
- Explore how standardized symptom capture supports triage prioritization and provides insights for the future of oncology care.

## Method for ARGOS-2

- Patients undergoing anti-cancer treatment are invited to complete a regular questionnaires on the Cureety platform, based on CTCAE, tailored to each treatment and cancer context.
- A triage prioritization classification is generated by Cureety : **Stable**, **Minor**, **Serious** or **Critical**
- Patients do not view the color-coded classification. Instead, they receive personalized guidance based on the overall assessment (e.g., contacting their care team for higher-risk responses) along with symptom-specific management recommendations when relevant.
- Alerts generated enable healthcare professionals to prioritize patients requiring review and to initiate appropriate interventions according to local care pathways.
- The Cureety platform has been successfully adopted across diverse healthcare settings, ranging from smaller practices to large institutions and across both public and private oncology centers, demonstrating sustained real-world adoption and scalability.

## Results

Between October 2019 and March 2026, **48,137 patients** completed over **800,000 questionnaires** across **107 healthcare institutions** in France.

High patient and HCP satisfaction and engagement demonstrate the feasibility and scalability of digital remote monitoring into cancer care.

**Table 1: Baseline demographics**

| Characteristic | N | % |
|---|---|---|
| All patients | 48,137 | 100.0 |
| **Gender** | | |
| Female | 27,413 | 56.9 |
| Male | 20,724 | 43.1 |
| **Age** | | |
| < 40 | 1,631 | 3.4 |
| 40-59 | 11,950 | 24.8 |
| 60-79 | 2,845 | 59.1 |
| ≥ 80 | 6,100 | 12.7 |
| **Cancer Stage** | | |
| Localized | 13,211 | 27.4 |
| Locally advanced | 7,618 | 15.8 |
| Metastatic | 19,590 | 40.7 |
| Other / n.d. | 7,718 | 16.0 |
| **Monitoring Type** | | |
| Autonomous (App) | 40,296 | 83.7 |
| Assisted (Phone Call) | 7,841 | 16.3 |





**Figure 1: Distribution of patients surveyed across cancer types**





**Figure 2: Patient questionnaires completed across cancer treatment modalities**

## Key takeaways

→ Standardized patient-reported symptom assessment and triage classification is feasible at a national scale, enabling consistent interpretation of treatment-related toxicity signals across diverse oncology settings.

→ This standardized framework provides a foundation for clinical decision support, precision monitoring, and future AI-enabled and digitally integrated oncology care.

Access additional figures & references